ライフサイエンスコーパス: TEG

1 TEG functionalization of the hydrazone switch allows for

2 TEG has been designated as a "Safer Chemical" by the US

3 th clot strength (ROTEM r: -0.52, p = 0.002; TEG r: -0.40, p < 0.0001).

4 agulation kinetics (ROTEM r: 0.46; p = 0.01; TEG r: 0.49; p < 0.0001) and inversely correlated with c

5 usion strategy or standard of care (SOC; 1:1 TEG:SOC).

6 hours from arrival (21.8% CCA group vs 7.1% TEG group) (P = 0.032).

7 ), and more platelets units [CCA: 0.0 (0-1), TEG: 0.0 (0-0)] (P = 0.041) in the first 2 hours of resu

8 units as the TEG patients [CCA: 5.0 (2-11), TEG: 4.5 (2-8)] (P = 0.317), but more plasma units [CCA:

9 ene glycol)-capped gold nanoparticles (NH(2)-TEG-AuNPs) was used to fabricate an in-house lateral flo

10 This Bi(2)Te(3)/Bi(0.5)Sb(1.5)Te(3) TEG exhibits S = 250 muV/K per pair and P = 0.2 nW per p

11 317), but more plasma units [CCA: 2.0 (0-4), TEG: 0.0 (0-3)] (P = 0.022), and more platelets units [C

12 2.5 mg TAM implant + 1000 ppm genistein (2.5 TEG); E2 implant + 5 mg TAM implant (5 TE), and E2 impla

13 ant +5 mg TAM implant +1000 ppm genistein (5 TEG).

14 full factorial optimization technique and a TEG configuration for simultaneous optimization of power

15 h-rate PVD/R2R compatibility, we fabricate a TEG using Virtual Cathode Deposition (VCD), a novel high

16 tests except platelet count (PLT) and in all TEG parameters, on the first day of infection compared w

17 nfection resolved, while the r, k, and alpha TEG parameters significantly worsened in the 8 patients

18 ere included in an intent-to-treat analysis (TEG = 56, CCA = 55).

19 2287 adult trauma patients (ROTEM: 2019 and TEG: 968) were enrolled.

20 In both our ROTEM (n = 34) and TEG (n = 239) ICH cohorts, hemoglobin concentrations dir

21 without ischemic events by aggregometry and TEG (p < 0.001 for both measurements).

22 t reactivity as measured by aggregometry and TEG were the only variables significantly related to isc

23 t reactivity at baseline by aggregometry and TEG, respectively.

24 to define threshold parameters for ROTEM and TEG.

25 ately after insertion of the PCI sheath, and TEG tracing was performed within 4 h post-sampling.

26 evaluated with routine hemostasis tests and TEG on admission and/or the first day with signs of infe

27 meters correlated with TEG reaction time and TEG functional fibrinogen, especially when stratified by

28 d antifibrinolytics or blood products before TEG testing.

29 show the least sequence conservation between TEG sulfotransferases.

30 gulopathy and nonvariceal upper GI bleeding, TEG-guided transfusion strategy leads to a significantly

31 However, both TEG-DVBE-containing adhesives developed more and deeper

32 yielded correction to normal ranges in both TEG and CBT end points at 5 to 15 mg/kg and 15 to 20 mg/

33 encing cocktail in an immobilization buffer (TEG/ethanol), the DNA fragments demonstrated a high affi

34 /- 2% after PCI (p = NS), and aggregation by TEG was 5 +/- 9% before PCI and 6 +/- 14% after PCI (p =

35 fter aspirin (p < 0.001), and aggregation by TEG was 86 +/- 14% before and 5 +/- 7% at 24 h after asp

36 0% aggregation by LTA or >50% aggregation by TEG.

37 be managed either by an MTP goal directed by TEG or by CCA (ie, international normalized ratio, fibri

38 Tumor cell lysis by TEG A3 was monitored using the Incucyte S3 live-cell ima

39 es in viscoelasticity were then monitored by TEG.

40 SF from the excimer state of Me, C6, TEG, and EH takes place in tauSF = 22, 336, 195, and 120

41 lly justify curves and parameters for common TEG assays (Functional Fibrinogen, Citrated Native, Plat

42 ially higher power density than conventional TEGs.

43 hexaethylene glycol hydrophilic units (DEG, TEG, and HEG, respectively).

44 el system was able to adequately demonstrate TEG A3 reactivity toward targets expressing an isoform o

45 Utilization of a goal-directed, TEG-guided MTP to resuscitate severely injured patients

46 DOX-TEG-TAM retains 60% of the affinity of 4-hydroxytamoxife

47 DOX-TEG-TAM uptake was inhibited in a dose-dependent manner

48 DOX-TEG-TAM was also taken up by the AEBS-negative, ER-posit

49 DOX-TEG-TAM was taken up by four AEBS-positive cell lines to

50 xorubicin-formaldehyde conjugate, called DOX-TEG-TAM, was found to possess superior cell growth inhib

51 The lead compound, DOX-TEG-TAM, bearing a triethylene glycol tether, binds the

52 ine as a function of time showed initial DOX-TEG-TAM localization in cytosol, in contrast to initial

53 mer, triethylene glycol divinylbenzyl ether (TEG-DVBE), with urethane dimethacrylate (UDMA) or pyrome

54 ke exposure (NEG); predominant THS exposure (TEG); and mixed SHS and THS exposure (MEG).

55 The corresponding rTEG-FF TEG MA was 46 mm.

56 ponding value for functional fibrinogen (FF) TEG maximum amplitude (MA) was 19 mm.

57 ord-high open-circuit voltage among flexible TEGs is achieved, reaching 1 V/cm(2) at a temperature di

58 High-throughput production of flexible TEGs is currently dominated by printing techniques, limi

59 illator-embedded triboelectric generator (FO-TEG) is applicable for both impulse excitation and sinus

60 nstrate the energy harvesting behavior of FO-TEG, lighting of an array of LEDs is demonstrated using

61 from the inherently packaged structure of FO-TEG.

62 ediction accuracies of 100% for NEG, 88% for TEG, followed by 71% for MEG.

63 Blood samples for TEG were obtained immediately after insertion of the PCI

64 UC) was calculated, and threshold values for TEG and ROTEM parameters with 70% sensitivity were inclu

65 obic "B" blocks and hydrophilic PFS-b-(PEO-g-TEG) "A" segments were prepared and their hierarchical s

66 PFS-b-(PEO-g-TEG) cylindrical micelles of controlled length with low

67 ne glycol (TEG), abbreviated as PFS-b-(PEO-g-TEG).

68 nd materials for a thermoelectric generator (TEG) to be used in a (PV) system.

69 that consists of a triboelectric generator (TEG) and a thin-film electroluminescent (TFEL) lamp.

70 Thermoelectric generators (TEGs) are an excellent candidate for powering wearable e

71 ed that segmented thermoelectric generators (TEGs) can operate over large thermal gradient and thus p

72 Flexible thermoelectric generators (TEGs) can provide uninterrupted, green energy from body-

73 Thermoelectric generators (TEGs) fabricated using additive manufacturing methods ar

74 study, segmented thermoelectric generators (TEGs) have been simulated with various state-of-the-art

75 garding the involvement of TE-derived genes (TEGs) in tumor pathogenesis.

76 imide substrate, a sputtered Bi(2)Te(3)/GeTe TEG with Seebeck coefficient (S) of 140 muV/K per pair a

77 erlock the PBI-QS with tetraethylene glycol (TEG) cross-linkers, yielding QS-TEG(lock) with increased

78 h biotin (bioactive) and triethylene glycol (TEG) (antifouling) functionality.

79 and proprietary blend of triethylene glycol (TEG) and inert ingredients designed for continuous antim

80 2-4 bearing solubilizing triethylene glycol (TEG) chains of equal length on both molecule ends, but a

81 core and two hydrophilic triethylene glycol (TEG) chains on the other.

82 orm the incorporation of triethylene glycol (TEG) moieties, that consistently increase the frequency

83 S-b-PAGE) decorated with triethylene glycol (TEG), abbreviated as PFS-b-(PEO-g-TEG).

84 thyl (Me), n-hexyl (C6), triethylene glycol (TEG), and 2-ethylhexyl (EH) substituents at the 2,5-posi

85 duced using 400 MW PEG (polyethylene glycol),TEG (triethylene glycol), alpha-MG (methyl-alpha-glucosi

86 cy experiments by the US EPA, as well as GP (TEG) safety and toxicology, are also discussed.

87 ve landmark of the tracheoesophageal groove (TEG - defined here as the space between the trachea and

88 The hybrid TEG-DVBE-containing dental adhesives generated equivalen

89 n independent predictor of a hypercoagulable TEG profile and platelet count, endotoxin, Protein C and

90 hrombin III deficiencies and hypercoagulable TEG parameters were prevalent among patients with VTE.

91 i-Factor Xa deficiencies and hypercoagulable TEG parameters, including elevated coagulation index (>3

92 e independent predictors of a hypocoagulable TEG profile.

93 INR > 3 was associated with: hypocoagulable TEG profile with heparin-like effect; falls in thrombin

94 ne dosing in patients following CPB improved TEG r-time and reduced the dose administered relative to

95 In TEG assays, tPA significantly decreased clot strength (m

96 Clotting rapidity (angle alpha in TEG) was decreased from a baseline value of 73.3 +/- 1.1

97 Clot strength (maximum amplitude in TEG) was decreased from a baseline value of 72.2 +/- 1.4

98 re classified in NEG, 16% were classified in TEG, and 8% were classified in MEG.

99 Secondary endpoints included ratio of kaolin TEG r-time pre-CPB to the same metric following protamin

100 The primary endpoint was kaolin TEG r-time measured 3 minutes after protamine administra

101 performance of the fixed "end-on" Lis-mAb-NH-TEG-AuNPs LFS for detecting L. monocytogenes was evaluat

102 performance of the fixed "end-on" Lis-mAb-NH-TEG-AuNPs LFS in detecting L. monocytogenes.

103 Therefore, the fixed "end-on" Lis-mAb-NH-TEG-AuNPs LFS serves as a promising candidate for a poin

104 The fixed "end-on" Lis-mAb-NH-TEG-AuNPs LFS showed no cross-reactivity with other path

105 (LFS), namely, the fixed "end-on" Lis-mAb-NH-TEG-AuNPs LFS.

106 Here, systematic analyses of TEG expression across human cancer reveal a prominent ro

107 Objective: To evaluate the effectiveness of TEG-adjusted prophylactic enoxaparin dosing among trauma

108 oscopy (PEIS) together with Raman mapping of TEG-templated hydration shells point to a key role of th

109 gle x-ray scattering done in the presence of TEG suggests that for further deformation-beyond a 9% de

110 demonstrated the tumor target specificity of TEG A3, lysing tumor cells within 48 h.

111 he optimal properties and design concepts of TEGs reported here can pave the way for delivering the n

112 Additive manufacturing of TEGs requires active thermoelectric particles to be disp

113 It is demonstrated that multiple types of TEGs are applicable to the self-powered system, indicati

114 , to facilitate treatment decisions based on TEG curves.

115 e statistical tools, we provide near-optimum TEG configuration with only 25 experiments as compared t

116 oelastic coagulation tests (such as ROTEM or TEG) have emerged as practical, rapid and sensitive diag

117 rospective way to construct high performance TEGs with greatly enhanced efficiency and output power d

118 quick, control-oriented models that predict TEG curve outputs from input blood protein concentration

119 Preoperative TEG may reliably identify group of recipients at greater

120 The maximum amplitude (MA) on preoperative TEG was significantly higher in patients diagnosed with

121 ransform the manufacting method for printing TEGs by eliminating the need of long-duration and high-t

122 ant coagulopathy before invasive procedures, TEG-guided transfusion strategy leads to a significantly

123 lene glycol (TEG) cross-linkers, yielding QS-TEG(lock) with increased water solvation, controlled gro

124 r-TEG estimated percent lysis was categorized as PF when >

125 r-TEG was performed by adding tissue factor to uncitrated

126 In addition, r-TEG identified patients with an increased risk of early

127 All had admission r-TEG and CCTs.

128 We have previously shown that admission r-TEG results are available faster than CCTs and predict p

129 Coagulopathy was defined as r-TEG clot strength = G < 5.3 dynes/cm.

130 We correlated r-TEG values [activated clotting time (ACT), r, k, alpha,

131 The charge for r-TEG ($317) was similar to the 5 CCTs ($286).

132 Overall, r-TEG correlated with CCTs.

133 The r-TEG data was clinically superior to results from 5 CCTs.

134 Recently, rapid thrombelastography (r-TEG) has become recognized as a comprehensive assessment

135 Rapid thrombelastography (r-TEG) offers point of care comprehensive assessment of th

136 Admission CCTs can be replaced with r-TEG.

137 We hypothesized that r-TEGs more reliably predict blood component transfusion t

138 Citrated Native, Platelet Mapping, and Rapid TEG), and verify results with trauma patient clotting da

139 As this resolved, TEG demonstrated that both developed a marked hypercoagu

140 alyses, we constructed algorithms for ROTEM, TEG, and CCTs to be used in addition to ratio driven tra

141 nships between baseline hemoglobin and ROTEM/TEG results were separately assessed across patient coho

142 ave a consistent, measurable impact on ROTEM/TEG testing in ICU admitted patients, which appear to be

143 However, segmented TEGs are still in early stages of development due to the

144 tal factors on the optimization of segmented TEGs is also studied.

145 for optimizing the performance of segmented TEGs.

146 ize output power and efficiency of segmented TEGs.

147 The simulated TEG power generation with different heat sink designs, h

148 llocated to TEG-guided transfusion strategy (TEG group; n = 49) or standard-of-care (SOC) group (n =

149 ineered to express a defined gammadelta TCR (TEG A3).

150 procedure bleeding was rare, indicating that TEG thresholds should be reevaluated.

151 The TEG gene cluster, a glycopeptide biosynthetic gene clust

152 The TEG group would receive FFP if the reaction time (r) was

153 The TEG provides high-voltage alternating electric output, w

154 imilar number of red blood cell units as the TEG patients [CCA: 5.0 (2-11), TEG: 4.5 (2-8)] (P = 0.31

155 onent of OPE2 can be readily shielded by the TEG chains, leading to only one aggregation pathway.

156 Induced charges pumped onto the lamp by the TEG generate an electric field that is sufficient to exc

157 Furthermore, the TEG-DVBE-containing materials may find wider dental appl

158 d blood product transfusions versus 5 in the TEG group (100% vs. 16.7%; P < 0.0001).

159 he CCA group (36.4%) compared with 11 in the TEG group (19.6%) (P = 0.049).

160 ents (FFP, PLTs, and cryoprecipitate) in the TEG group compared with the SOC group.

161 Although 7 (14.3%) patients in the TEG group received no blood component transfusion, there

162 Survival in the TEG group was significantly higher than the CCA group (l

163 In the TEG group, none received FFP alone (P < 0.0001 vs. SOC),

164 In the TEG group, only 26.5% patients were transfused with all

165 In contrast, the decreased capability of the TEG chains to effectively shield larger hydrophobic core

166 s media disclose a different tendency of the TEG chains to fold back and enwrap the hydrophobic molec

167 f compatibility factor s from one end of the TEG leg to the other, even if s values of two ends diffe

168 The results showed that the TEG with pin fin heat sink design (H3) made from alumini

169 Ns were identified within or adjacent to the TEG and 6.9% were lateral to the tracheal surface; 100%

170 gh considered potentially detrimental to the TEG performance, these effects, if well-regulated, do no

171 Ns were identified within or adjacent to the TEG.

172 Furthermore, this TEG is integrated with a wavelength-selective metamateri

173 en heparinase and standard thrombelastogram (TEG) is associated with a decreased risk of VTE.

174 ivated clotting time, and thrombelastograph (TEG).

175 Thrombelastography (TEG) is a method that is used to conduct global assays t

176 et aggregation (LTA) and thrombelastography (TEG) platelet mapping were performed on the blood of hea

177 belastometry (ROTEM) and thrombelastography (TEG) were collected prospectively at 6 European trauma c

178 ittance aggregometry and thrombelastography (TEG) will be at increased risk for poststenting ischemic

179 ine hemostasis tests and thrombelastography (TEG), a global test of hemostatic function.

180 y the viscoelastic assay thrombelastography (TEG) improves survival compared with an MTP guided by co

181 od samples were drawn for thrombelastograpy (TEG) and active metabolite assay.

182 through pretransplant thromboelastographic (TEG) data among other known risk factors, to identify ri

183 Thromboelastography (TEG) provides a more comprehensive global coagulation as

184 Thromboelastography (TEG) provides a more comprehensive global coagulation as

185 elastometry (ROTEM) and thromboelastography (TEG), and a third surgical ICU cohort receiving ROTEM we

186 thrombography (CAT) and thromboelastography (TEG).

187 f clot strength such as thromboelastography (TEG), which help evaluate coagulation status in numerous

188 ndices were measured by thromboelastography (TEG).

189 Results from thromboelastography (TEG) suggest that SAA causes atypical coagulation with a

190 At 12 h thromboelastography (TEG) demonstrated increased clot formation rate, associa

191 ent model would improve thromboelastography (TEG) parameters and reduce the dose of protamine adminis

192 ostasis as exhibited in thromboelastography (TEG) and cuticle bleeding time (CBT) tests.

193 scribe the first use of thromboelastography (TEG) in the management of 2 cases of Ebola virus disease

194 ge <18 years with rapid thromboelastography (TEG) on arrival and documented time of injury were queri

195 nvariceal source) were randomly allocated to TEG-guided transfusion strategy (TEG group; n = 49) or s

196 Sixty patients were randomly allocated to TEG-guided transfusion strategy or standard of care (SOC

197 ations of 0.04-0.5 mg/m(3) (corresponding to TEG concentrations of 0.025 to 0.287 mg/m(3)).

198 ciency up to 11%) as compared to traditional TEGs, comprising of single thermoelectric (TE) material.

199 Two TEG parameters between the case and control groups were

200 Furthermore, the water solubility of UDMA/TEG-DVBE resins was reduced approximately 89% in compari

201 Here, we report a high-performance wearable TEG with superior stretchability, self-healability, recy

202 RAR coagulation parameters correlated with TEG reaction time and TEG functional fibrinogen, especia

203 red standard dosing (30 mg twice daily) with TEG-adjusted enoxaparin dosing (35 mg twice daily) for 1